© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake/File Photo
WASHINGTON (Reuters) – Illumina Inc (NASDAQ:) filed an appeal late on Monday against an order by the U.S. Federal Trade Commission, which is demanding that the company divest cancer diagnostic test maker Grail Inc because of concern that its ownership would stifle competition in the U.S. market for cancer tests.
This text was written byObserveAustin Rogers is a REIT specialist with knowledgeable background in industrial actual property. He writes about...
This text was written byObserveMy major space of focus might be on figuring out firms of remarkable caliber, with a...
From a post-COVID stock scramble to a $40,000 leap into liquidation, Bert Leffel, CEO of AuctionFuel and Listernaut, has seen...
This text was written byComply withI'm a worth centered investor, conducting elementary analysis on sectors like however not restricted to...
This text was written byObserveWriter of the Macro Traits & Inflection Factors E-newsletter. I spent 5 years as a co-founder...
With consciousness of the environmental challenges related to quick vogue and the linear “take-make-dispose” mannequin, the business is at a...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
